Señales en vivo de APLI.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 10:45):

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada...

Stats
Volumen de hoy	3 000.00
Volumen promedio	192 619
Capitalización de mercado	4.85M
EPS	$0 ( 2024-02-11 )
Próxima fecha de ganancias	( $-0.0100 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.000
ATR14	$0 (0.00%)

APPILI THERAPEUTICS INC Correlación

10 Correlaciones Más Positivas
ISV.TO	0.832

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

APPILI THERAPEUTICS INC Finanzas

Annual	2022
Ingresos:	$334 177
Beneficio Bruto:	$327 911 (98.12 %)
EPS:	$-0.0813

FY	2022
Ingresos:	$334 177
Beneficio Bruto:	$327 911 (98.12 %)
EPS:	$-0.0813

FY	2022
Ingresos:	$1.39M
Beneficio Bruto:	$1.39M (100.00 %)
EPS:	$-0.380

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.240

Financial Reports:

No articles found.

APPILI THERAPEUTICS INC

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.